Brainstorm Health: Civica Rx Headquarters, Lilly Pfizer Pain Drug, Flu Season
Brainstorm Health Daily: April 19, 2019 Happy Friday, readers! Last year, a coal.....»»
Big Drug Makers Sue to Block Mandatory Price Disclosures in TV Ads: Brainstorm Health
Amgen, Merck, Eli Lilly, and others sued to block the Trump administration's proposed rule on drug TV ads. Happy Friday, readers! In what may be one of the least unexpected lawsuits against .....»»
Brainstorm Health: Royal Baby, All of Us, Pfizer Heart Drug Approval
Brainstorm Health Daily: May 6, 2019 .....»»
Brainstorm Health: ADHD and Overdoses, Pfizer and the Drug Supply Chain, Geisinger DNA Testing
Brainstorm Health Daily: May 22, 2018 Good afternoon, readers. This is Sy. The opioid crisis ravaging America has understandably become the biggest public health story of the past few years. But the specter of potential overmedication, and the conseq.....»»
Brainstorm Health: Puerto Rico Maria Deaths, Roche Lung Cancer Drug, Planned Parenthood Setback
Brainstorm Health Daily: May 29, 2018 Hurricane season does not officially begin until Friday, June 1--though that start date is somewhat artificial as Subtropical Storm Alberto made clear yesterday--driving its way across .....»»
Pfizer, Eli Lilly non-opioid pain drug nears finish line
A new non-opioid drug for osteoarthritis pain being developed.....»»
Brainstorm Health: Kavanaugh Vote, Hepatitis E, Lilly and Pfizer FDA Approvals
Brainstorm Health Daily: September 28, 2018 The televised hearing before the Senate Committee on the Judiciary yesterday centered o.....»»
Brainstorm Health: J&J CEO on Drug Prices, Polio-Like Condition, Pfizer Breast Cancer Drug
Brainstorm Health Daily: October 16, 2018 Hello, readers. This is Sy. The Fortune Gl.....»»
New pain drug from Pfizer and Eli Lilly shows promise as opioid alternative
The drug, from Pfizer and Eli Lilly, has had a checkered history but shows promise in osteoarthritis pain......»»
Pfizer, Eli Lilly say experimental arthritis drug tanezumab hits FDA snag
Pfizer Inc. and Eli Lilly and Co. said Thursday that a joint advisory committee of the U.S. Food and Drug Administration has vote.....»»
FDA panel votes 19-1 that Pfizer OA pain drug risks may outweigh benefits
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Pfizer"s earnings outlook for 2021 tops expectations, but stock falls
Shares of Pfizer Inc. dropped 2.1% in morning trading Tuesday, even after the drug maker provided an upbeat earnings outlook for this year. Speaking at the J.P. Morgan Health Care Conferenc.....»»
St. Luke"s receives first shipment from nonprofit generic drug company
St. Luke’s University Health Network, whose hospitals include its Upper Bucks Campus in Milford Township, said Thursday it received its first shipment of injectable drugs from Civica Rx. Utah-based Civica Rx was formed in 2018 to combat chronic sho.....»»
Is Pfizer Raising Drug Prices Too Much in 2020?
Ahead of election years, the cost and future of health care has become one of the top debates for better than two decades now. Most politicians say that they want to lower prescription drug costs.........»»
The Wall Street Journal: FDA requires box warnings for Pfizer drug Xeljanz
The U.S. Food and Drug Administration is requiring that health warnings be added to Pfizer Inc.’s drug Xeljanz, advising patients they could experience a higher risk of blood clots or death with a specific dose......»»
Former FDA Chief Gottlieb Heads to Pfizer’s Board: Brainstorm Health
Gottlieb has long had ties to pharmaceutical and health care companies. Good afternoon, readers – and a short one for you amid some busy times. Former Food and Drug Admin.....»»
What the $63 Billion AbbVie Allergan Deal Says About the Drug Industry: Brainstorm Health
AbbVie's acquisition of the Botox maker isn't a great reflection on the state of big pharma innovation. Good afternoon, readers. Let’s parse the.....»»
Bristol-Myers Squibb Loses $6 Billion in Value on Celgene Deal Setback: Brainstorm Health
Bristol Myers surprised investors, announcing it would spin off Celgene's popular drug Otezla to address antitrust concerns. Happy Monday, readers! Bristol-Myers Squibb hasn’t exactly had a p.....»»
The Ratings Game: Pfizer, Eli Lilly, Bristol-Myer and J&J initiated with buy ratings by Goldman Sachs
Goldman Sachs started coverage of some big drug stocks on Tuesday in a bullish note......»»